Cargando…
Plasma growth differentiation factor-15 is an independent marker for aggressive disease in endometrial cancer
OBJECTIVE: Better biomarkers are needed in order to identify patients with endometrial carcinoma at risk of recurrence and who may profit from a more aggressive treatment regimen. Our objective was to explore the applicability of plasma growth differentiation factor 15 (GDF-15) as a marker for recur...
Autores principales: | Engerud, Hilde, Hope, Kirsten, Berg, Hege Fredriksen, Fasmer, Kristine Eldevik, Tangen, Ingvild Løberg, Haldorsen, Ingfrid Salvesen, Trovik, Jone, Krakstad, Camilla |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6333370/ https://www.ncbi.nlm.nih.gov/pubmed/30645608 http://dx.doi.org/10.1371/journal.pone.0210585 |
Ejemplares similares
-
Whole‐Volume Tumor MRI Radiomics for Prognostic Modeling in Endometrial Cancer
por: Fasmer, Kristine E., et al.
Publicado: (2020) -
Blood Metabolites Associate with Prognosis in Endometrial Cancer
por: Strand, Elin, et al.
Publicado: (2019) -
Preoperative 18F-FDG PET/CT tumor markers outperform MRI-based markers for the prediction of lymph node metastases in primary endometrial cancer
por: Fasmer, Kristine E., et al.
Publicado: (2020) -
Mismatch repair markers in preoperative and operative endometrial cancer samples; expression concordance and prognostic value
por: Berg, Hege F., et al.
Publicado: (2022) -
HER2 expression patterns in paired primary and metastatic endometrial cancer lesions
por: Halle, Mari Kyllesø, et al.
Publicado: (2018)